Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, Iain A Bruce
{"title":"Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series","authors":"Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, Iain A Bruce","doi":"10.1186/s13023-024-03253-3","DOIUrl":null,"url":null,"abstract":"Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme. MPS IVA is associated with a wide gamut of respiratory and airway disorders that manifest in a continuum of severity. In individuals exhibiting severe phenotypic expression, terminal stages of the disease frequently culminate in life-threatening, critical airway obstruction. These manifestations of end-stage disease are engendered by an insidious progression of multi-level airway pathologies, comprising of tracheomalacia, stenosis, tortuosity and 'buckling'. Historically, the management of end-stage airway disease has predominantly leaned towards palliative modalities. However, contemporary literature has posited that the potential benefits of tracheal resection with aortopexy, performed under cardiopulmonary bypass (CPB), may offer a promising therapeutic option. In this context, we report on outcomes from patients undergoing a novel approach to tracheal resection that is combined with manubrial resection, leading to improved airway calibre, obviating the requisition for CPB. In this study, seven patients with severe MPS IVA exhibited clinical symptoms and radiological evidence indicative of advanced airway obstruction. All patients had a tracheal resection with a partial upper manubriectomy via transcervical approach, which did not require CPB. The surgical cohort consisted of 5 females and 2 males, the median age was 16 years (range 11-19) and the median height was 105.6cm (range 96.4-113.4). Postoperatively, significant improvements were seen in forced expiratory volume in 1 second (FEV1), with a mean increase of 0.68 litres (95% CI: 0.45-0.91; SD: 0.20). Notably, other spirometry variables also showed meaningful improvements, providing evidence of positive treatment effects. Furthermore, there were no major long-term complications, and the procedure resulted in a significant enhancement in patient-reported domains using PedsQL (version 4.0). This study represents the largest case series to date, on tracheal resection in patients with severe MPS IVA. Our findings demonstrate the effectiveness of the transcervical approach with partial manubriectomy for improving respiratory function and quality of life for individuals with advanced airway obstruction. Tracheal resection presents a promising treatment modality for severe cases of MPS IVA. Successful outcomes rely on meticulous multidisciplinary assessment, judicious decision-making, and appropriate timing of tracheal surgery. Further research and long-term follow-up studies are warranted to validate the long-term efficacy and safety of this approach.","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-024-03253-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme. MPS IVA is associated with a wide gamut of respiratory and airway disorders that manifest in a continuum of severity. In individuals exhibiting severe phenotypic expression, terminal stages of the disease frequently culminate in life-threatening, critical airway obstruction. These manifestations of end-stage disease are engendered by an insidious progression of multi-level airway pathologies, comprising of tracheomalacia, stenosis, tortuosity and 'buckling'. Historically, the management of end-stage airway disease has predominantly leaned towards palliative modalities. However, contemporary literature has posited that the potential benefits of tracheal resection with aortopexy, performed under cardiopulmonary bypass (CPB), may offer a promising therapeutic option. In this context, we report on outcomes from patients undergoing a novel approach to tracheal resection that is combined with manubrial resection, leading to improved airway calibre, obviating the requisition for CPB. In this study, seven patients with severe MPS IVA exhibited clinical symptoms and radiological evidence indicative of advanced airway obstruction. All patients had a tracheal resection with a partial upper manubriectomy via transcervical approach, which did not require CPB. The surgical cohort consisted of 5 females and 2 males, the median age was 16 years (range 11-19) and the median height was 105.6cm (range 96.4-113.4). Postoperatively, significant improvements were seen in forced expiratory volume in 1 second (FEV1), with a mean increase of 0.68 litres (95% CI: 0.45-0.91; SD: 0.20). Notably, other spirometry variables also showed meaningful improvements, providing evidence of positive treatment effects. Furthermore, there were no major long-term complications, and the procedure resulted in a significant enhancement in patient-reported domains using PedsQL (version 4.0). This study represents the largest case series to date, on tracheal resection in patients with severe MPS IVA. Our findings demonstrate the effectiveness of the transcervical approach with partial manubriectomy for improving respiratory function and quality of life for individuals with advanced airway obstruction. Tracheal resection presents a promising treatment modality for severe cases of MPS IVA. Successful outcomes rely on meticulous multidisciplinary assessment, judicious decision-making, and appropriate timing of tracheal surgery. Further research and long-term follow-up studies are warranted to validate the long-term efficacy and safety of this approach.
莫基奥综合征终末期危重气道阻塞患者气管切除术的新方法:英国病例系列报道
粘多糖病(MPS)IVA 型是一种罕见的溶酶体贮积症,由 N-乙酰-半乳糖胺-6-硫酸酯酶(GALNS)畸变引起。MPS IVA 与多种呼吸道和气道疾病相关,这些疾病的严重程度各不相同。在表现出严重表型的个体中,疾病的终末期往往会导致危及生命的严重气道阻塞。这些终末期疾病的表现是由气管畸形、狭窄、迂曲和 "弯曲 "等多层次气道病变的隐匿性进展引起的。从历史上看,终末期气道疾病的治疗主要倾向于姑息治疗。然而,当代文献认为,在心肺旁路(CPB)下进行气管切除和主动脉瓣成形术的潜在益处可能会提供一种有前途的治疗选择。在这种情况下,我们报告了患者接受气管切除术的结果,这种气管切除术结合了人工肺切除术,从而改善了气道口径,无需进行 CPB。在这项研究中,七名重症 MPS IVA 患者表现出临床症状和放射学证据,表明气道阻塞已进入晚期。所有患者均接受了气管切除术,并通过经颈部入路进行了部分上半部气管切除术,无需进行 CPB。手术组包括 5 名女性和 2 名男性,中位年龄为 16 岁(11-19 岁不等),中位身高为 105.6 厘米(96.4-113.4 厘米不等)。术后,1 秒用力呼气容积(FEV1)明显改善,平均增加了 0.68 升(95% CI:0.45-0.91;SD:0.20)。值得注意的是,其他肺活量变量也出现了有意义的改善,为积极的治疗效果提供了证据。此外,该手术没有出现重大的长期并发症,而且患者使用 PedsQL(4.0 版)报告的领域也有显著改善。这项研究是迄今为止关于重症 MPS IVA 患者气管切除术的最大规模病例系列研究。我们的研究结果表明,经颈部气管部分切除术能有效改善晚期气道阻塞患者的呼吸功能和生活质量。对于严重的 MPS IVA 病例,气管切除术是一种很有前景的治疗方式。成功的结果取决于细致的多学科评估、明智的决策和气管手术的适当时机。为了验证这种方法的长期疗效和安全性,有必要开展进一步的研究和长期随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信